Britain and America have hammered out a landmark commercial pact that will keep no duties on UK pharmaceutical products going into the American market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has committed to increase funding on medicines through the National Health Service (NHS). This commitment guarantees that tariffs on these crucial products will stay at nothing for a period of three years.
This deal is in response to earlier statements to dramatically increase duties on patented pharmaceutical products, with figures mentioned reaching one hundred percent.
"This arrangement with the Britain strengthens the international landscape for new treatments and brings much-needed equity to American-British pharmaceutical trade," an announcement noted.
Commercial Importance
Drugs constitute one of the Britain's biggest exports to the US, which is by far the largest buyer for large companies like GSK and AstraZeneca.
Statistics reveal that in the year leading up to the third quarter, the UK shipped pharmaceutical products worth billions to the US. This amount accounted for nearly one-fifth of British export trade in that period.
"This guarantee protects employment, increases capital expenditure and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," a minister commented.
Specific British Pledges
The agreement includes several notable pledges from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new therapies to be too expensive by a quarter.
- Boosted Medicine Funding: There is a aim to raise total health service expenditure on drugs from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must pay back to the NHS to stay within budget will be restricted at fifteen percent. In the past, rebates were more than twenty percent.
Broader Context
The deal comes amid a ongoing dispute between the sector and the British authorities over spending levels and NHS adoption.
This friction were exacerbated by claims that American consumers were paying a premium for the same drugs than people in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been halted or cancelled, while multi-billion-dollar investments have been pledged toward American operations.
One official stated that the NHS had to spend more on drugs, noting that its expenditure on drugs had declined as a proportion of its overall budget over the last ten years.
